In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Vera Therapeutics, with a price target of $90.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Arthur He CFA has given his Buy rating due to a combination of factors that highlight the potential of Vera Therapeutics’ atacicept. The recent FDA approval of sibeprenlimab for IgAN, which did not include a UPCR cutoff, sets a positive precedent for atacicept, suggesting a broader patient population could benefit from its use. This development is promising for the commercialization of atacicept, as it demonstrated similar efficacy in clinical trials without the presence of neutralizing anti-drug antibodies, which have been a concern for sibeprenlimab.
Additionally, Arthur He CFA’s valuation of Vera Therapeutics supports the Buy rating, with a 12-month price target of $90. This target is based on a risk-adjusted net present value analysis of atacicept’s projected revenues, factoring in a 12% discount rate and a 2% terminal growth rate. The analysis includes the company’s net cash and cash equivalents, leading to a confident outlook on the stock’s potential. Despite potential risks such as clinical, regulatory, and competitive challenges, the overall assessment remains optimistic.
He CFA covers the Healthcare sector, focusing on stocks such as Vera Therapeutics, Nektar Therapeutics, and Satellos Bioscience. According to TipRanks, He CFA has an average return of 27.7% and a 50.00% success rate on recommended stocks.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $70.00 price target.